Kinex names Michael Murphy director
This article was originally published in Scrip
Buffalo, New York-based Kinex Pharmaceuticals has named Michael Murphy to its board of directors. In parallel, Dr Jean-Pierre Sommadossi is stepping down from the company's board, but will continue to act as a senior advisor to Kinex's CEO Dr Johnson Lau. Mr Murphy is a senior partner at law firm DLA Piper. He is also a founding member of the private equity and angel investment firm Shadow Rock with holdings in the pharmaceutical, technology, real estate and other sectors. He said as an investor with Kinex he has been "consistently impressed" by the firm which he says has a "strong and impressive pipeline of clinical oncology drug candidates." Mr Murphy is based out of DLA Piper's New York, London and Hong Kong offices.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.